Clinical Trial Update: A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC [Phase 2]

View source ↗

Summary

Phase 2 study of SHR3680 in combination with SHR3162 for metastatic castration-resistant prostate cancer has been terminated. The trial (NCT04102124) is sponsor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• SHR3162 (SHR3162)
• SHR3680

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: TERMINATED